Form 4: Arcellx Director Sells Shares After Option Exercise
Insider Transaction Report
Arcellx Director David Charles Lubner exercised stock options and subsequently sold 6,000 shares of common stock for a significant profit under a pre-arranged trading plan.
Summary
- Director David Charles Lubner, a Director of Arcellx, Inc. (ACLX), exercised 6,000 stock options for common stock at an exercise price of $6.28 per share.
- Concurrently, Lubner sold 6,000 shares of Arcellx common stock at a price of $75.00 per share.
- These transactions occurred on January 20, 2026.
- The sale was executed pursuant to a Rule 10b5-1 trading plan that the Reporting Person entered into on September 29, 2025.
- Following these transactions, Lubner directly beneficially owns 21,659 shares of common stock and 59,405 stock options.
Sentiment
Score: 6
Explanation: The director's significant profit from the option exercise and sale is positive for the individual, and the use of a 10b5-1 plan indicates pre-planning, which is generally viewed neutrally to positively from a governance perspective. However, a director selling shares can sometimes be perceived as a slight negative by the market, balancing the overall sentiment to moderately positive.
Positives
- The director realized a substantial profit from exercising options at $6.28 and selling at $75.00, indicating significant appreciation in the company's stock value since the option grant.
- The use of a Rule 10b5-1 trading plan demonstrates pre-planned transactions, which can reduce concerns about opportunistic insider trading.
Negatives
- A director selling shares, even under a 10b5-1 plan, reduces their direct equity stake in the company.
Future Outlook
NA
Industry Context
This filing is a standard insider transaction report and does not provide specific details related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The sale of shares was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 29, 2025, which is a mechanism to allow insiders to sell shares without being accused of trading on material non-public information. | 09/29/2025 | Enhances transparency and reduces potential for insider trading allegations by pre-scheduling transactions. |
Stakeholder Impact
- Shareholders may view the director's sale of shares as a signal, though the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling.
- The significant profit realized by the director highlights the potential value creation for long-term equity holders.
Key Dates
| Date | Description |
|---|---|
| 06/09/2021 | Vesting Commencement Date for the stock option. |
| 09/29/2025 | Date Rule 10b5-1 trading plan was entered into by the Reporting Person. |
| 01/20/2026 | Transaction Date for stock option exercise and common stock sale. |
| 06/09/2031 | Expiration Date of the stock option. |
Keywords
Arcellx, ACLX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.